All content on this site is intended for healthcare professionals only. By acknowledging this message and accessing the information on this website you are confirming that you are a Healthcare Professional. If you are a patient or carer, please visit the MPN Advocates Network.

The MPN Hub uses cookies on this website. They help us give you the best online experience. By continuing to use our website without changing your cookie settings, you agree to our use of cookies in accordance with our updated Cookie Policy

Introducing

Now you can personalise
your MPN Hub experience!

Bookmark content to read later

Select your specific areas of interest

View content recommended for you

Find out more
  TRANSLATE

The MPN Hub website uses a third-party service provided by Google that dynamically translates web content. Translations are machine generated, so may not be an exact or complete translation, and the MPN Hub cannot guarantee the accuracy of translated content. The MPN Hub and its employees will not be liable for any direct, indirect, or consequential damages (even if foreseeable) resulting from use of the Google Translate feature. For further support with Google Translate, visit Google Translate Help.

Steering CommitteeAbout UsNewsletterContact
Visit:
ALL Hub

ALL Hub

AML Hub

AML Hub

GvHD Hub

GvHD Hub

Lupus Hub

Lupus Hub

Lymphoma Hub

Lymphoma Hub

Multiple Myeloma Hub

Multiple Myeloma Hub

PsOPsA Hub

PsOPsA Hub

LOADING
You're logged in! Click here any time to manage your account or log out.
LOADING
You're logged in! Click here any time to manage your account or log out.
Steering CommitteeAbout UsNewsletterContact

Brought to you by

Scientific Education Support logo

The MPN Hub is an independent medical education platform, sponsored by AOP Health and GSK, and supported through an educational grant from Bristol Myers Squibb. The funders are allowed no direct influence on our content. The levels of sponsorship listed are reflective of the amount of funding given. View funders.

TypesTherapeuticsCongressesTrialsExpert OpinionsEducational ResourcesDRUG UPDATES
2023-08-25T15:45:17.000Z

Clinical trial club | Luspatercept for the treatment of patients with anemic myelofibrosis: Q&A session

By Oscar Williams, Lauren Lett
Featured
Aaron Gerds
Jean-Jacques Kiladjian
Aug 25, 2023
Share:

Bookmark this article

Jean-Jacques Kiladjian and Aaron Gerds concluded the live clinical trial club webinar, "NCT03194542 trial: Luspatercept for the treatment of patients with anemic myelofibrosis," by discussing questions submitted by the audience.

More about...
LuspaterceptMPN Hub clinical trial clubsMyelofibrosisMyelofibrosis Clinical Trial Club 2023Myeloproliferative neoplasms

Your opinion matters

What do you consider to be the highest unmet need for patients with myelofibrosis?​
26 votes - 22 days left ...

Newsletter

Subscribe to get the best content related to MPN delivered to your inbox